<p>在昨天發佈的一份報告中，美國銀行證券的傑森·傑伯裏重申了對 Axsome Therapeutics 的買入評級，目標價為 276.00 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>傑森·傑伯裏給予買入評級是基於與 Auvelity 擴展商業機會和股票估值相關的多種因素。他強調，管理層對 Auvelity 的新目標是 80 億美元的峯值銷售目標，得益於最近在阿爾茨海默病激動症方面的批准和有利標籤，這一目標在當前股價中並未完全反映，甚至與更保守的共識峯值估計相比也是如此。</p>
<p>他還指出，即將推出的阿爾茨海默病激動症治療、擴大到 630 人的銷售團隊同時推廣抑鬱症和阿爾茨海默病適應症，以及中樞神經系統藥物中指示疊加的證明效益，都是可以釋放出顯著上行空間的關鍵增長驅動因素。此外，他提到在重度抑鬱症方面的強勁早期進展、上升的重度抑鬱症峯值銷售假設以及加強的長期管道，這些都支撐了他重申的買入評級和 276 美元的目標價。</p>
<p>根據 TipRanks，傑伯裏是一位五星級分析師，平均回報率為 18.9%，成功率為 61.32%。傑伯裏覆蓋醫療保健行業，關注的股票包括 Ionis Pharmaceuticals、Alkermes 和 BioMarin Pharmaceutical。</p>
<p>在昨天發佈的另一份報告中，Needham 也對該股票給予了買入評級，目標價為 267.00 美元。</p>

AXSM

<p>來自美國銀行證券的 Jason Gerberry 重申了對 Axsome Therapeutics 的買入評級，並將目標價提高至 276 美元。他指出，Auvelity 在阿爾茨海默病激動症中的商業機會正在擴大，以及管理層 80 億美元的峯值銷售目標是關鍵因素。即將推出的產品和增強的銷售團隊預計將推動增長。Needham 也給予了買入評級，目標價為 267 美元。Gerberry 是一位五星級分析師，平均回報率為 18.9%，成功率為 61.32%</p>

<p>In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Axsome Therapeutics, with a price target of $276.00.</p>
<div class="lb-trans"><p>在昨天發佈的一份報告中，美國銀行證券的傑森·傑伯裏重申了對 Axsome Therapeutics 的買入評級，目標價為 276.00 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>Jason Gerberry has given his Buy rating due to a combination of factors related to Auvelity’s expanding commercial opportunity and the stock’s valuation. He highlights that management’s new $8 billion peak sales ambition for Auvelity, supported by the recent approval in Alzheimer’s disease agitation and a favorable label, is not fully reflected in the current share price, even versus more conservative consensus peak estimates.</p>
<div class="lb-trans"><p>傑森·傑伯裏給予買入評級是基於與 Auvelity 擴展商業機會和股票估值相關的多種因素。他強調，管理層對 Auvelity 的新目標是 80 億美元的峯值銷售目標，得益於最近在阿爾茨海默病激動症方面的批准和有利標籤，這一目標在當前股價中並未完全反映，甚至與更保守的共識峯值估計相比也是如此。</p>
</div><p>He also points to the upcoming Alzheimer’s agitation launch, the enlarged 630-person sales force promoting both depression and Alzheimer’s indications, and the proven benefits of indication stacking in CNS drugs as key growth drivers that can unlock substantial upside. Additionally, he notes robust early traction in major depressive disorder, rising peak MDD sales assumptions, and a strengthened longer-term pipeline, all of which underpin his reiterated Buy rating and increased price objective of $276 per share.</p>
<div class="lb-trans"><p>他還指出，即將推出的阿爾茨海默病激動症治療、擴大到 630 人的銷售團隊同時推廣抑鬱症和阿爾茨海默病適應症，以及中樞神經系統藥物中指示疊加的證明效益，都是可以釋放出顯著上行空間的關鍵增長驅動因素。此外，他提到在重度抑鬱症方面的強勁早期進展、上升的重度抑鬱症峯值銷售假設以及加強的長期管道，這些都支撐了他重申的買入評級和 276 美元的目標價。</p>
</div><p>According to TipRanks, Gerberry is a 5-star analyst with an average return of 18.9% and a 61.32% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alkermes, and BioMarin Pharmaceutical.</p>
<div class="lb-trans"><p>根據 TipRanks，傑伯裏是一位五星級分析師，平均回報率為 18.9%，成功率為 61.32%。傑伯裏覆蓋醫療保健行業，關注的股票包括 Ionis Pharmaceuticals、Alkermes 和 BioMarin Pharmaceutical。</p>
</div><p>In another report released yesterday, Needham also assigned a Buy rating to the stock with a $267.00 price target.</p>
<div class="lb-trans"><p>在昨天發佈的另一份報告中，Needham 也對該股票給予了買入評級，目標價為 267.00 美元。</p>
</div>

Buy Rating Reiterated as Auvelity’s Expanded Alzheimer’s Opportunity Drives Upgraded $276 Price Target

- 美國銀行證券的傑森·傑伯裏重申對 Axsome Therapeutics 的買入評級，目標價 276 美元。  
- 傑伯裏認為管理層的 80 億美元銷售目標未在當前股價中完全反映。  
- 近期阿爾茨海默病激動症的批准預計將推動公司增長。

Tip Ranks

Axsome Therap

美國銀行

Ionis制藥

阿爾凱默斯

拜瑪林制藥

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

由於 Auvelity 在阿爾茨海默症領域的擴展機會，買入評級被重申，目標價上調至 276 美元